

**Establishing a List of Qualifying Pathogens That Have the Potential to Pose a Serious  
Threat to Public Health**

**Public Hearing – December 18, 2012**

**Panel Members**

Kristiana Brugger, J.D., LL.M.  
Regulatory Counsel  
Division of Regulatory Policy I  
Office of Regulatory Policy  
CDER, FDA

John Farley, M.D., M.P.H.  
Deputy Director, Office of  
Antimicrobial Products  
Office of New Drugs  
CDER, FDA

Jane Knisely, Ph.D.  
National Institute of Allergy and  
Infectious Diseases (NIAID)  
National Institutes of Health (NIH)

Sumati Nambiar, M.D., M.P.H.  
Deputy Director for Safety  
Division of Anti-Infective Products  
Office of Antimicrobial Products  
Office of New Drugs  
CDER, FDA

David Roeder, M.S.  
Associate Director for Regulatory Affairs  
Office of Antimicrobial Products  
Office of New Drugs  
CDER, FDA

Julia Tierney, J.D.  
Associate Chief Counsel for Drugs  
Office of Chief Counsel  
FDA

Edward Cox, M.D., M.P.H.  
Director, Office of Antimicrobial  
Products  
Office of New Drugs  
CDER, FDA

Joanne Holmes, M.B.A.  
Associate Director for Regulatory  
Affairs  
Office of Counter-Terrorism  
and Emergency Coordination  
CDER, FDA

Katherine Laessig, M.D.  
Deputy Director  
Division of Anti-Infective Products  
Office of Antimicrobial Products  
OND, CDER, FDA

Melissa Robb  
Associate Director for Regulatory  
Affairs  
Office of Medical Policy Initiatives  
Office of Medical Policy  
CDER, FDA

Steven Solomon, M.D.  
Director, Office of Antimicrobial Resistance  
Division of Healthcare Quality Promotion  
National Center for Emerging and Zoonotic  
Infectious Diseases  
Centers for Disease Control and  
Prevention (CDC)

Joseph Toerner, M.D., M.P.H.  
Associate Director for Medical Affairs  
Office of Antimicrobial  
Products  
Office of New Drugs  
CDER, FDA